GenScript Biotech's ESG Rating Upgrade
GenScript Biotech Corporation (HK.1548), a prominent provider of life science research and manufacturing services, has recently achieved a significant milestone with its upgrade to an AA ESG rating from MSCI. This acknowledgment highlights the company's dedication to product safety and human capital development, alongside continuous improvements in environmental and governance practices.
Understanding the MSCI ESG Rating
MSCI, a leading global index provider, rates companies based on their ability to manage environmental, social, and governance (ESG) risks. Companies are evaluated on a scale from CCC (laggard) to AAA (leader). The AA rating awarded to GenScript positions it as an ESG leader within the biotech community, underscoring its serious commitment to sustainability.
The Impact of the AA Rating
Sherry Shao, the Rotating CEO of GenScript Biotech, emphasized the importance of this rating by stating that it is a testament to their robust ESG performance. Integrating sustainability into the core of their operations enhances their resilience and generates long-term value for investors and stakeholders alike. This recognition reinforces their mission to promote health and sustainability through biotechnology.
Commitment to Responsible Practices
GenScript's ongoing commitment to sustainable practices is noteworthy. As a participant in the United Nations Global Compact (UNGC), the company follows ten universal principles regarding human rights, labor, environment, and anti-corruption. Additionally, its alignment with the Pharmaceutical Supply Chain Initiative (PSCI) showcases its efforts to foster sustainable supply chains in the pharmaceutical sector.
Recognition from Various Platforms
This year, GenScript has not only achieved an AA rating but also received a Silver Medal from EcoVadis and a 'Low Risk' ESG rating from Morningstar Sustainalytics. Its inclusion in the FTSE4Good Index Series adds to its reputation as a responsible corporate entity. Furthermore, the Science Based Targets initiative (SBTi) has validated its carbon reduction targets, reinforcing its proactive stance against climate change.
Overview of GenScript Biotech's Operations
Founded in 2002, GenScript Biotech Corporation operates from its headquarters in New Jersey. The company aims to accelerate healthcare and consumer goods innovation by equipping researchers and enterprises with essential tools to develop transformative treatments and products. With a team exceeding 5,500 employees, GenScript has successfully served over 200,000 customers across more than 100 countries.
Frequently Asked Questions
What is the significance of the AA rating for GenScript?
The AA rating signifies that GenScript is recognized as a leader in ESG practices, reflecting its commitment to sustainability and responsible corporate behaviors.
How does MSCI determine ESG ratings?
MSCI evaluates companies based on their exposure to industry-specific ESG risks and their capability to manage those risks relative to peers.
What initiatives does GenScript participate in for sustainability?
GenScript is involved in the United Nations Global Compact and the Pharmaceutical Supply Chain Initiative to promote responsible business practices.
What recognitions has GenScript achieved this year?
This year, GenScript has received a Silver Medal from EcoVadis and a 'Low Risk' ESG rating from Morningstar Sustainalytics, among other accolades.
What is GenScript's mission?
GenScript's mission is to 'Make People and Nature Healthier through Biotechnology,' focusing on delivering innovative solutions in healthcare.
